ATHE logo

ATHE
Alterity Therapeutics Ltd - ADR

8,863
Mkt Cap
$81.93M
Volume
4,734.00
52W High
$7.00
52W Low
$2.66
PE Ratio
-7.81
ATHE Fundamentals
Price
$4.65
Prev Close
$4.52
Open
$4.56
50D MA
$3.83
Beta
0.87
Avg. Volume
22,520.74
EPS (Annual)
-$0.7383
P/B
2.26
Rev/Employee
$0.00
$17.04
Loading...
Loading...
News
all
press releases
News Placeholder
Alterity Therapeutics Gets Positive FDA Feedback On ATH434 Phase 3 Study
(RTTNews) - Alterity Therapeutics Limited (ATHE) on Monday said it received positive feedback from the U.S. Food and Drug Administration following a Type C meeting regarding its planned Phase 3 program for ATH434 in Multiple System Atrophy (MSA...
Nasdaq News: Markets·10d ago
News Placeholder
Alterity Therapeutics Gains FDA Backing For Phase 3 MSA Trial
(RTTNews) - Alterity Therapeutics (ATHE, ATH.AX) announced that it has received positive regulatory feedback following a Type C Meeting with the U.S. Food and Drug Administration (FDA) regarding its planned Phase 3 development program for ATH434 in Multiple System Atrophy (MSA...
Nasdaq News: Markets·1mo ago
News Placeholder
Alterity Therapeutics Announces Appointment Of Daniel Claassen As Chief Medical Advisor
(RTTNews) - Alterity Therapeutics Limited (ATHE), Wednesday announced the appointment of Daniel Claassen as Chief Medical Advisor, effective March 2026...
Nasdaq News: Markets·2mo ago
News Placeholder
Alterity Therapeutics Stock Doubles Premarket On Positive MSA Trial Results: Retail Excitement Soars
A 50mg dose of its ATH434 showed 8% reduction in clinical progression of early-stage multiple system atrophy vs. placebo.
Stocktwits·1y ago
<
...
1
>

Latest ATHE News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.